Adrenomed–Informa: investor conference, 201905 supply service Adrenomed presents at BioEquity Europe 2019 in Barcelona

	Period	2019-05-20 ï¿½ 2019-05-21
	Partner, 1st	Adrenomed AG
	Partner, 2nd	EBD Group AG (CH)
	Today	EBD Group GmbH (DE)
	Group	Informa plc (Group)
	Product	BioEquity Europe 2019 Barcelona
	Product 2	adrecizumab
	Person	Hein, Frauke (Deutsche Biotech Innovativ 201211 Managing Director of MLDx GmbH + Adrenomed)

Adrenomed AG. (5/6/19). "Press Release: Adrenomed AG Takes Part in Three Upcoming Conferences". Hennigsdorf.

Adrenomed AG, the vascular integrity company, announced today its participation at three upcoming conferences in Europe and the USA. Adrenomed representatives will be available for one-on-one meetings at the following events:

Swiss Biotech Day 2019 and Annual General Assembly of the Swiss Biotech Association
May 07, 2019, Congress Center, Basel, Switzerland
https://swissbiotechday.ch/home/

20th Annual Bio€quity Europe
May 20 – 21, 2019, Crowne Plaza Barcelona Fira Center, Barcelona, Spain
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will give a company presentation on May 20, 16:30 CET, room Rossini 2.
https://www.biocentury.com/conferences/bio€quity-europe-2019

BIO International Convention 2019
June 3 – 6, 2019, Pennsylvania Convention Center, Philadelphia (PA), USA
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will represent the company and give a presentation.
https://convention.bio.org/

About Adrenomed

Adrenomed AG is a German privately-financed, clinical stage biopharmaceutical company. Adrenomed´s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company’s lead product candidate Adrecizumab is a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials.

Contact

Adrenomed AG
Frauke Hein, Ph.D. (Chief Business Officer)
phone: +49 (0)3302 2077814
fhein@adrenomed.com

Media Inquiries
MC Services AG
Eva Bauer/Julia von Hummel
phone: +49 (0)89 21022880
adrenomed@mc-services.eu

Record changed: 2019-05-12

More documents for Adrenomed AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)